Amneal (AMRX) Q1 FY26 earnings call

Amneal Pharmaceuticals announced the strategic acquisition of Kashiv BioSciences, aiming to become a fully integrated global biosimilars leader and America's #1 affordable medicines company. This move, supported by strong Q1 FY26 results and raised full-year guidance, diversifies its portfolio and extends its growth profile well into the 2030s, leveraging Kashiv's R&D and manufacturing capabilities with Amneal's commercial engine.